Application of Cilp1 as a biomarker for renal fibrosis

By detecting the expression level of Cilp1 and combining with TGF-β1, it verifies its prediction in renal fibrosis, solving the problem of difficulty in early and accurate diagnosis of renal fibrosis in the prior art, and providing a high sensitivity and high specificity diagnosis Based on this, the effectiveness of Cilp1 as a biomarker of renal fibrosis was verified.

CN115508565BInactive Publication Date: 2024-11-15成都医学院第一附属医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211288045.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-20
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to accurately diagnose and monitor renal fibrosis in the early stage, cannot keenly capture microscopic lesion information during the inflammatory response period, and lacks high sensitivity and high specificity biomarkers.

Method used

Cartilage intermediate layer protein 1 (Cilp1) is used as a biomarker of renal fibrosis. By detecting the expression level of Cilp1 in serum and renal tissues, combining TGF-β1 as a fibrosis indicator, the prediction of Cilp1 was verified and in animal models. Verify its effectiveness.

Benefits of technology

It was confirmed that Cilp1 is significantly related to renal fibrosis, has high sensitivity and high specificity, and can serve as a non-invasive diagnostic biomarker, providing a basis for early diagnosis and evaluation of renal fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003900172490000081
    Figure BDA0003900172490000081
  • Figure HDA0003900172500000011
    Figure HDA0003900172500000011
  • Figure HDA0003900172500000021
    Figure HDA0003900172500000021
Patent Text Reader

Abstract

The present invention discloses the application of Cilp1 as a renal fibrosis biomarker, and relates to the technical field of renal fibrosis diagnosis and treatment. The present invention confirms through clinical trials, various animal experiments and cell experiments that Cilp1 is significantly positively correlated with renal fibrosis, and Cilp1 can be used as a non-invasive diagnostic biomarker for renal fibrosis, with high sensitivity and high specificity; the present invention provides the application of Cilp1 as a renal fibrosis biomarker in the diagnosis of renal fibrosis products, and provides a basis for the early diagnosis of renal fibrosis by developing relevant Cilp1 detection kits, etc., and detecting the relative expression level of Cilp1 in renal tissue, renal tubular epithelial cells and serum of patients with renal fibrosis. At the same time, the application of Cilp1 as a renal fibrosis biomarker disclosed in the present invention can predict renal fibrosis and its severity through Cilp1, and provide guidance and reference for the treatment, diagnosis and prognosis of renal fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of diagnosis and treatment of renal fibrosis, and in particular to the application of Cilp1 as a renal fibrosis biomarker. Background Art

[0002] Renal fibrosis is the main common pathological link in the progression of chronic kidney disease (CKD) caused by various causes, including glomerular sclerosis and renal interstitial fibrosis. Its pathological characteristics are damage to renal intrinsic cells, infiltration of inflammatory cells, activation and proliferation of myofibroblasts and fibroblasts, accumulation of extracellular matrix (collagen fibers, fibronectin, laminin), loss of renal intrinsic cells, atrophy and collapse of renal tubules, and vascular rarefaction, which ultimately lead to the destruction of normal renal structure. Renal fibrosis marks irreversible renal damage, so early diagnosis of renal fibrosis and treatment of the cause are the key to delaying the progression of CKD.

[0003] Currently, imaging methods such as ultrasound and magnetic resonance imaging are often used to evaluate patients' renal fibrosis, but these technologies can only diagnose renal fibrosis at a macroscopic level and cannot keenly capture the microscopic lesion information during the inflammatory response period of renal fibrosis. Biomarkers can not only evaluate or quantitatively measure the biological and pathological processes of a disease, but also serve as therapeutic targets for the disease. Biomarkers are involved in all aspects of the disease process, and their levels change with the activity or progression of the disease process. Therefore, clarifying the biomarkers of renal fibrosis will help to accurately diagnose renal fibrosis and target treatment at an early stage.

[0004] Liu Qiuyu et al. Research progress in diagnostic biomarkers for renal fibrosis [J]. Molecular Biomedicine, 2019. The report included renal injury markers, inflammatory and profibrotic factor markers, microRNAs markers and new biomarkers, and screened out renal fibrosis diagnostic markers with high sensitivity and specificity, which are expected to replace classical renal pathology diagnosis.

[0005] Cartilage intermediate layer protein 1 (Cilp1) is an extracellular matrix protein that inhibits myocardial interstitial fibrosis and can provide a new strategy for intervening in the process of myocardial fibrosis. Literature reports that Cilp1 is an antagonist of transforming growth factor (TGF)-β and an extracellular matrix (ECM) protein involved in myocardial fibrosis signaling. Cilp1 RNA is upregulated in animal models of left ventricular (LV) pressure overload and left ventricular myocardial infarction, and Cilp1 protein levels are significantly increased in myocardial tissue of patients with aortic stenosis or myocardial infarction. Cilp1 has a potential role as a new biomarker for RV and LV pathological remodeling, which is associated with RV maladaptation and ventriculoarterial uncoupling in the setting of pulmonary hypertension. However, existing technologies have not reported studies on the association of Cilp1 with renal fibrosis. Summary of the invention

[0006] The purpose of the present invention is to provide the application of Cilp1 as a biomarker for renal fibrosis, confirming that Cilp1 is significantly positively correlated with renal fibrosis, and Cilp1 can be used as a non-invasive diagnostic biomarker for renal fibrosis with high sensitivity and high specificity.

[0007] In order to achieve the above technical objectives and the above technical effects, the present invention is implemented through the following technical solutions:

[0008] Application of Cilp1 as a biomarker for renal fibrosis.

[0009] Furthermore, the relative expression level of the biomarker Cilp1 in renal tissue, renal tubular epithelial cells and serum of subjects with renal fibrosis is upregulated compared with subjects without renal fibrosis.

[0010] The application of Cilp1 as a renal fibrosis biomarker of the present invention is to collect serum from normal people and patients with chronic kidney disease (stages 1-5), and detect the content of Cilp1 in the serum using an ELISA kit;

[0011] Comparison of serum Cilp1 between patients with chronic renal failure and healthy controls, ELISA results of serum Cilp1 between patients with chronic renal failure and healthy controls showed that the serum concentration of Cilp1 in patients with chronic renal failure was higher than that in normal controls; the results can confirm that Cilp1 can be used as an evaluation indicator.

[0012] The application of Cilp1 as a renal fibrosis biomarker of the present invention is to detect the degree of renal fibrosis by Masson staining of renal tissues collected from patients with chronic kidney disease (stages 1-5) that meet the standards, and to detect the expression of Cilp1 in the kidney by immunofluorescence technology, and to evaluate the prediction of Cilp1 by using TGF-β1 as a fibrosis indicator;

[0013] Masson staining of kidney tissues of patients with kidney disease, calculating the percentage of fibrosis to reflect the degree of tissue fibrosis; Correlation analysis was performed on the immunofluorescence intensity of Cilp1 in patients, with a correlation coefficient of R = 0.3063;

[0014] At the same time, the comparison of Masson's area (%) in renal tissues of patients with renal disease with the immunofluorescence intensity of Cilp1 further validated Cilp1 as a biomarker for renal fibrosis.

[0015] The application of Cilp1 as a renal fibrosis biomarker of the present invention is verified by establishing an animal model in a targeted manner, and the UUO rat test includes:

[0016] S1: Construction of rat models of sham operation group and UUO experimental group;

[0017] Specifically, the rats were fed adaptively for one week, and then the two groups of rats were anesthetized by intraperitoneal injection of 5% chloral hydrate. After local hair shaving, the rats were routinely disinfected and draped with a perforated towel. The skin and muscles were cut along the midline of the abdomen, the kidneys and ureters were freed, and the middle part of the left ureter was lifted with a tissue clamp. The muscles and skin of the sham operation group were routinely sutured, and the ureters of the UUO group were clamped with hemostatic forceps. The left ureter near the renal pelvis was ligated twice at both ends with 4-0 silk thread, the ureter was cut, and then the muscles and skin were routinely sutured.

[0018] S2: Rats were killed 21 days later, and kidney tissue specimens were collected. The degree of renal fibrosis was observed by HE and Masson staining. The expression of Cilp1 in the kidney was detected by immunofluorescence technique, and TGF-β1 was used as a fibrosis index to evaluate the prediction of Cilp1.

[0019] By comparing the Masson's area (%) and the Cilp1 immunofluorescence intensity in the kidney tissue of UUO rats, the immunofluorescence results showed that the Cilp1 fluorescence intensity increased with the increase of fibrosis degree;

[0020] Radiation-induced renal injury mouse test, including:

[0021] S1: Thirty C57 mice were randomly divided into three groups according to body weight, with 10 mice in each group, namely normal control group, 10gy radiation dose group and 20gy radiation dose group.

[0022] S2: After the mice were adaptively fed for one week, the normal control group mice were not intervened normally, and the radiation group mice were irradiated with electron beams once in the abdominal cavity of the mice in the single 10gy radiation dose group (10gy) and the 20gy radiation dose group, respectively. The mice in both groups were killed after 2 months;

[0023] S3: Mouse kidney tissues were collected, and the degree of renal fibrosis was observed by HE and Masson staining. The expression of Cilp1 in the kidney was detected by immunofluorescence technology, and TGF-β1 was used as a fibrosis indicator to evaluate the prediction of Cilp1.

[0024] First, the Masson staining of the kidney tissue of each group of mice was calculated to calculate the percentage of fibrosis, reflecting the degree of tissue fibrosis; the immunofluorescence intensity of Cilp1 expressed in the kidney tissue of the corresponding mice was analyzed for correlation:

[0025] The two are correlated, with a correlation coefficient of R = 0.686;

[0026] Comparison of Masson's area (%) and Cilp1 immunofluorescence intensity in the kidney tissue of mice with radiation-induced renal injury showed that the Cilp1 fluorescence intensity increased with the degree of fibrosis;

[0027] Validate the application of Cilp1 as a biomarker for renal fibrosis.

[0028] The invention uses Cilp1 as a renal fibrosis biomarker. The renal tubular epithelial cell line (HK-2) is induced to model fibrosis (epithelial-mesenchymal transition) by TGF-β1. The expression of Cilp1 in a normal cell group and an induced intervention group is compared, and Western blotting and qPCR techniques are used for detection.

[0029] Another object of the present invention is to provide the use of Cilp1 as a renal fibrosis biomarker in diagnosing renal fibrosis products;

[0030] The products for diagnosing renal fibrosis include but are not limited to reagents and kits.

[0031] A kit for diagnosing renal fibrosis, comprising a reagent for detecting the up-regulation of the relative expression level of Cilp1 in renal tissue, renal tubular epithelial cells and patient serum.

[0032] Another object of the present invention is to provide the use of Cilp1 in predicting renal fibrosis and its severity.

[0033] Beneficial effects of the present invention:

[0034] The present invention provides the use of Cilp1 as a renal fibrosis biomarker. The present invention confirms that Cilp1 is significantly positively correlated with renal fibrosis. Cilp1 can be used as a non-invasive diagnostic biomarker for renal fibrosis with high sensitivity and high specificity.

[0035] Provides the application of Cilp1 as a renal fibrosis biomarker in the diagnosis of renal fibrosis products, and provides a basis for the early diagnosis of renal fibrosis by detecting the relative expression level of Cilp1 in renal tissue, renal tubular epithelial cells and patient serum.

[0036] Of course, any product implementing the present invention does not necessarily need to achieve all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The ELISA results of serum Cilp1 in the chronic renal failure patient group and the healthy population group described in Example 1 of the present invention;

[0038] Figure 2 This is a correlation analysis between the area percentage (%) of Masson in the kidney tissue of the kidney disease patient and the immunofluorescence intensity of Cilp1 in Example 2 of the present invention;

[0039] Figure 3 The results of Masson's area (%) and Cilp1 immunofluorescence intensity in kidney tissue of patients with kidney disease described in Example 2 of the present invention;

[0040] Figure 4 The results of Masson's area (%) and Cilp1 immunofluorescence intensity in kidney tissue of UUO rats described in Example 3 of the present invention;

[0041] Figure 5 The results of Masson's area (%) and Cilp1 immunofluorescence intensity in kidney tissue of mice with radiation-induced renal injury described in Example 4 of the present invention;

[0042] Figure 6 This is the correlation analysis between the area percentage (%) of Masson in the kidney tissue of mice with radiation-induced renal injury and the immunofluorescence intensity of Cilp1 as described in Example 4 of the present invention;

[0043] Figure 7 The Western blotting results of Clip1 protein in HK-2 cells described in Example 4 of the present invention;

[0044] Figure 8 This is the qPCR result of Clip1 gene expression in HK-2 cells described in Example 4 of the present invention; DETAILED DESCRIPTION

[0045] In order to more clearly illustrate the technical solution of the embodiment of the present invention, the present invention will be described in detail below with reference to the accompanying drawings.

[0046] Example 1

[0047] Clinical trial data analysis

[0048] Serum from 20 healthy subjects and patients with chronic kidney disease (stages 1-5) was collected, and the content of Cilp1 in serum was detected by ELISA kit; sera from 20 healthy subjects and patients with chronic kidney disease (stages 1-5) were collected, and the content of Cilp1 in serum was detected by ELISA kit. The results are as follows Figure 1 As shown:

[0049] Figure 1 In the figure, the horizontal axis is the grouping information (healthy group and chronic renal failure patient group); the vertical axis is the serum concentration of Cilp1; there is a difference in Clip1 content between the two groups.

[0050] The difference of Cilp1 in the serum of chronic renal failure patients and healthy people was compared. The ELISA results of serum Cilp1 in chronic renal failure patients and healthy people showed that the serum concentration of Cilp1 in chronic renal failure patients was higher than that in normal people; the results can confirm that Cilp1 can be used as an evaluation indicator.

[0051] Example 2

[0052] In this example, 12 patients with kidney disease who met the criteria were selected;

[0053] The degree of renal fibrosis was detected by Masson staining of renal tissues from patients with chronic kidney disease (stages 1-5) that met the criteria, and the expression of Cilp1 in the kidney was detected by immunofluorescence technology. TGF-β1 was used as a fibrosis indicator to evaluate the prediction of Cilp1, and the results were combined with clinical indicators (serum creatinine, blood urea nitrogen, etc.);

[0054] The data of patients with kidney disease are collected as follows:

[0055] Table 1 Data of patients with kidney disease

[0056]

[0057] like Figure 2 As shown, Masson staining of kidney tissue of patients with kidney disease was used to calculate the percentage of fibrosis, reflecting the degree of tissue fibrosis; the immunofluorescence intensity of Cilp1 of the corresponding patients was analyzed for correlation, and the correlation coefficient was R=0.3063;

[0058] like Figure 3As shown, the above patients numbered 2, 6, and 12 were selected to compare the area (%) of Masson in the kidney tissue of patients with kidney disease with the immunofluorescence intensity of Cilp1;

[0059] from Figure 3 As can be seen from the left side view, the Masson staining results of the three patients showed that the degree of fibrosis increased in sequence (from top to bottom, the above patients numbered 2, 6, and 12);

[0060] from Figure 3 As can be seen from the right side view, the immunofluorescence results show that the fluorescence intensity of Cilp1 increases with the degree of fibrosis. In the right side view, DAPI: cell nucleus; Cilp1: green; TGF-β1: red; Merge: Cilp1 and TGF-β1 overlap (from top to bottom, the above patients are numbered 2, 6, and 12);

[0061] Based on the correlation analysis between the area percentage (%) of Masson in renal tissue of patients with kidney disease and the immunofluorescence intensity of Cilp1, as well as the comparison between the area percentage (%) of Masson in renal tissue of patients with kidney disease and the immunofluorescence intensity of Cilp1, it can be seen that Cilp1 was further validated as a biomarker for renal fibrosis.

[0062] Example 3

[0063] UUO rat test

[0064] S1: Construction of rat models of sham operation group and UUO experimental group;

[0065] Specifically, the rats were fed adaptively for one week, and then the two groups of rats were anesthetized by intraperitoneal injection of 5% chloral hydrate. After local hair shaving, the rats were routinely disinfected and draped with a perforated towel. The skin and muscles were cut along the midline of the abdomen, the kidneys and ureters were freed, and the middle part of the left ureter was lifted with a tissue clamp. The muscles and skin of the sham operation group were routinely sutured, and the ureters of the UUO group were clamped with hemostatic forceps. The left ureter near the renal pelvis was ligated twice at both ends with 4-0 silk thread, the ureter was cut, and then the muscles and skin were routinely sutured.

[0066] S2: Rats were killed 21 days later, and kidney tissue specimens were collected. The degree of renal fibrosis was observed by HE and Masson staining. The expression of Cilp1 in the kidney was detected by immunofluorescence technique, and TGF-β1 was used as a fibrosis index to evaluate the prediction of Cilp1.

[0067] like Figure 4 As shown, the area (%) of Masson in the kidney tissue of UUO rats was compared with the immunofluorescence intensity of Cilp1: Figure 4It can be seen that the comparison of Masson's area (%) and Cilp1 immunofluorescence intensity in the renal tissue of the normal control group (Control) and the UUO model group (UUO) shows that the Cilp1 fluorescence intensity increases with the degree of fibrosis. (DAPI: cell nucleus; Cilp1: green; TGF-β1: red; Merge: Cilp1 and TGF-β1 overlap.

[0068] Figure 4 In the figure, Control is the normal group, UUO is the model group, and they correspond to the upper and lower contents in sequence. At the same time, DAPI: cell nucleus; Cilp1: green; TGF-β1: red; merge: Cilp1 and TGF-β1 co-staining comparison was performed. The results also confirmed that the immunofluorescence results showed that the fluorescence intensity of Cilp1 increased with the increase of fibrosis degree;

[0069] The application of Cilp1 as a biomarker for renal fibrosis was validated.

[0070] Example 4

[0071] Radiation-induced renal injury in mice

[0072] S1: Thirty C57 mice were randomly divided into three groups according to body weight, with 10 mice in each group, namely normal control group, 10gy radiation dose group and 20gy radiation dose group.

[0073] S2: After the mice were adaptively fed for one week, the normal control group mice were not intervened normally, and the radiation group mice were irradiated with electron beams once in the abdominal cavity of the mice in the single 10gy radiation dose group (10gy) and the 20gy radiation dose group, respectively. The mice in both groups were killed after 2 months;

[0074] S3: Mouse kidney tissues were collected, and the degree of renal fibrosis was observed by HE and Masson staining. The expression of Cilp1 in the kidney was detected by immunofluorescence technology, and TGF-β1 was used as a fibrosis indicator to evaluate the prediction of Cilp1.

[0075] First, the Masson staining of the kidney tissue of each group of mice was calculated to calculate the percentage of fibrosis, reflecting the degree of tissue fibrosis; the immunofluorescence intensity of Cilp1 expressed in the kidney tissue of the corresponding mice was analyzed for correlation:

[0076] like Figure 5 As shown, there is a correlation between the two, with a correlation coefficient of R = 0.686;

[0077] Comparison of Masson's area (%) and Cilp1 immunofluorescence intensity in the kidney tissue of mice with radiation-induced renal injury. Figure 6 As shown:

[0078] Mice with radiation-induced renal injury were divided into a normal control group (Control), a 10gy radiation dose group (10gy), and a 20gy radiation dose group (20gy);

[0079] Through DAPI: cell nucleus; Cilp1: green; TGF-β1: red; merge: Cilp1 and TGF-β1 co-staining experiment, from top to bottom are normal group, 10gy radiation dose group (10gy), 20gy radiation dose group (20gy). The results show that the correlation of radiation dose, and the immunofluorescence results show that the fluorescence intensity of Cilp1 increases with the increase of fibrosis degree;

[0080] The application of Cilp1 as a biomarker for renal fibrosis was validated.

[0081] Example 5

[0082] Renal tubular epithelial cell line (HK-2) was induced to fibrosis (epithelial-mesenchymal transition) by TGF-β1, and the expression of Cilp1 protein in the normal cell group and the induced intervention group was compared and detected by Western blotting and qPCR technology;

[0083] like Figure 7 As shown, the western blotting results of HK-2 cells:

[0084] The 4th and 5th generation HK-2 (renal tubular epithelial cells) were divided into two groups, a control group and a TGF-β1-induced group. The control group was not treated, and the TGFβ group was induced with 2ng / ml, 5ng / ml, 10ng / ml, and 20ng / ml of TGF-β1 cytokine for 24h. The protein expression of Cilp1 in the two groups was calculated.

[0085] Compared with the normal control group, the expression of Cilp1 gradually increased with the increase of TGF-β1 concentration;

[0086] like Figure 8 As shown, HK-2 cell qPCR results:

[0087] The 4th and 5th generation HK-2 (renal tubular epithelial cells) were divided into two groups, a control group and a TGFβ1-induced group. The control group was not treated, and the TGF-β1 group was induced with 10 ng / ml of TGF-β1 cytokine for 24 h. The mRNA expression of Cilp1 in the two groups was calculated.

[0088] Compared with the normal control group, the mRNA expression of Cilp1 was higher than normal. There was a significant difference in the mRNA expression of Cilp1 between the two groups (P≤0.05).

[0089] The present invention provides the use of Cilp1 as a renal fibrosis biomarker. The present invention confirms that Cilp1 is significantly positively correlated with renal fibrosis. Cilp1 can be used as a non-invasive diagnostic biomarker for renal fibrosis with high sensitivity and high specificity.

[0090] Provides the application of Cilp1 as a renal fibrosis biomarker in the diagnosis of renal fibrosis products, and provides a basis for the early diagnosis of renal fibrosis by detecting the relative expression level of Cilp1 in renal tissue, renal tubular epithelial cells and patient serum.

[0091] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. Application of Cilp1 as a renal fibrosis biomarker in the diagnosis of renal fibrosis products.

2. The use of Cilp1 as a renal fibrosis biomarker in a product for diagnosing renal fibrosis according to claim 1, characterized in that: The products for diagnosing renal fibrosis include but are not limited to reagents and kits.

3. A kit for diagnosing renal fibrosis, characterized in that: The kit comprises reagents for detecting the up-regulated expression level of Cilp1 in fibrotic renal tissue, renal tubular epithelial cells and patient serum.

4. Application of Cilp1 in the preparation of products for predicting renal fibrosis and its severity.

5. The use of Cilp1 according to claim 4 in preparing a product for predicting renal fibrosis and its severity, characterized in that: The relative expression levels of Cilp1 in renal tissue, renal tubular epithelial cells and patient serum were detected and then compared with those in patients with renal fibrosis at different stages.